Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6

European Journal of Pharmacology

Volumn 328, Issue 2-3, 1997, Pages 163-174

  D'Hahan, Nathalie ^a,b   Taouil, Karima ^a,b   Dassouli, Abdelilah ^a,b   Jean Emile Morel, ^a,b  

^a ECOLE CENTRALE PARIS   (France)

^b Dept de Biol Cell et Molec   (France)

Author keywords

Ca2+; Cardiomyopathy; Hypertrophy; Ischemia; Trimetazidine; Verapamil

Indexed keywords

ANTIISCHEMIC AGENT; CALCIUM; CALCIUM ANTAGONIST; TRIMETAZIDINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEART VENTRICLE HYPERTROPHY; LIVER HYPERTROPHY; LONGEVITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL TIME; SYRIAN HAMSTER;

EID: 0030961676     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)83042-7     Document Type: Article

References (47)

1. Askenasy N., Navon G. Volume-related activities of sodium ion transporters: multinuclear NMR studies of isolated rat hearts. Am. J. Physiol. 271:1996;H94-H106.
2. Boddeke E., Hugtenburg J., Jap W., Heynis J., Van Zwieten P. New anti-ischaemic drugs: cytoprotective action with no primary haemodynamic effects. Trends Pharmacol. Sci. 10:1989;397-400.
3. 2+ antagonist for the treatment of chronic artery disease. Controlled, double-blind study against placebo. Presse Med. 15:1986;1783-1787.
4. Brottier L., Barat J.L., Combe C., Boussens B., Bonnet J., Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur. Heart J. 11:1990;207-212.
5. Chiercha S.L., Fragasso G. Metabolic management of ischaemic heart disease. Eur. Heart J. 14(Suppl. G):1993;2-5.
6. Conway R.S., Natelson B.H., Chen W.H., Ting W. Enhanced coronary vasoconstriction in the Syrian myopathic hamster supports the microvascular spasm hypothesis. Cardiovasc. Res. 28:1994;320-324.
7. Dalla-Volta S., Maraglino G., Della-Valentino P., Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind cross-over study. Cardiovasc. Drugs Ther. 4:1990;853-860.
8. Davidoff A.J., Gwathmey J.K. Pathophysiology of cardiomyopathies. Part I. Animal models and humans Curr. Opin. Cardiol. 9:1994;357-368.
9. Detry J.M., Sellier P., Pennaforte S., Cokkinos D., Dargie H., Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br. J. Clin. Pharmacol. 37:1994;279-288.
10. Devynck M.A., Le Quan Sang K.H., Joulin Y., Mazeaud M. Acute membrane effects of trimetazidine in human platelets. Eur. J. Pharmacol. 245:1993;105-110.
11. Factor S.M., Cho S., Scheuer J., Sonnenblick E.H., Malhotra A. Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy. J. Am. Cell. Cardiol. 12:1988;1599-1604.
12. Fantini E., Demaison L., Sentex E., Grynberg A., Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J. Mol. Cell. Cardiol. 26:1994;949-958.
13. Finkel M.S. Verapamil regulation of a defective SR release channel in the cardiomyopathic hamster. Life Sci. 52:1993;1109-1119.
14. Freedman S.B., Richmond D.R., Ashley J.J., Kelly D.T. Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin. Pharmacol. Ther. 30:1981;644-652.
15. Fukuchi T., Kobayashi A., Kaneko M., Ichiyama A., Yamazaki N. Possible involvement of free radicals and antioxidants in the early stages of the development of cardiomyopathy in BIO 14.6 Syrian hamster. Jpn. Heart J. 32:1991;655-666.
16. Gilloteaux J., Bissler J.J., Kondolios P., Jarjoura D. Cardiomyocyte aging and hypertrophy: atrial and ventricular changes in normal and myopathic Syrian hamsters. J. Sub. Cytol. Pathol. 22:1990;249-257.
17. Godfraind T., Kazda S., Wibo M. Effects of a chronic treatment by nisoldipine, a calcium antagonistic dihydropyridine, on arteries of spontaneously hypertensive rats. Circ. Res. 68:1991;674-682.
18. 2+ transients from newborn rat cardiomyocytes in primary culture. Cell Calcium. 15:1994;265-275.
19. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
20. Hanton G., Barnes P., Shepperson N.B., Walley R. Effects of hydrochlorothiazide and captopril on the survival and heart weight of cardiomyopathic hamsters. Res. Commun. Chem. Pathol. Pharmacol. 81:1993;159-166.
21. Harpey C., Clauser P., Labrid C., Freyria J.L., Poirier J.P. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc. Drug Rev. 6:1989;292-312.
22. Jasmin G., Proschek L. Calcium and myopathic cell injury. An appraisal in the cardiomyopathic hamster. Can. J. Physiol. Pharmacol. 62:1984;891-898.
23. 1-adrenergic activity in cardiomyopathic Syrian hamster. Am. J. Physiol. 260:1991;H80-H88.
24. Katz, A.M., 1992. Physiology of the Heart, 2nd ed. Raven Press, New York, NY, p. 23.
25. Lagadic-Gossmann D., Le Prigent K., Feuvray D. Effects of trimetazidine on pHi regulation in the rat isolated ventricular myocyte. Br. J. Pharmacol. 117:1996;831-838.
26. 31P-NMR spectroscopy in the isolated rat heart. Arch. Int. Pharmacodyn. 286:1987;97-110.
27. Martoja, R., Martoja, A., 1967. Initiation aux Techniques de l'Histologie Animale. Masson, Paris, pp. 233-237.
28. Maupoil, V., Rochette, L., Tabard, A., Clauser, P., Harpey, C., 1990. Direct measurement of free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy: effect of trimetazidine. In: Emerit (Ed.), Antioxidants in Therapy and Preventive Medecine. pp. 373-376.
29. Mercadier J.-J., Lompre A.-M., Wisnewsky C., Samuel J.-L., Bercovicci J., Swynghedauw B., Schwartz K. Myosin isoenzymic changes in several models of rat cardiac hypertrophy. Circ. Res. 49:1981;525-532.
30. Métézeau P., Kieffer H., Lamy G., Delamare G. Laser scanning cytometry for analysis and preparation [in French]. Pathol. Biol. 41:1993;276-280.
31. Michaelides A.P., Vysoulis G.P., Bonoris P.E., Psaros Th.K., Papadopoulos P.D., Toutouzas P.K. Beneficial effects of trimetazidine in patients with stable angina under beta-blockers. Cardiovasc. Drug Ther. 1:1987;268-274.
32. Momomura S.-I., Nagai Y., Ogawa T., Bessho M., Yamashita H., Serizawa T. Increased tolerance of ventricular function and energy metabolism to hypoxia in cardiomyopathic hamsters. J. Mol. Cell. Cardiol. 25:1993;551-562.
33. Natelson B.H., Tapp W.N., Drastal S., Suarez R., Ottenweller J.E. Hamsters with coronary vasospasm are at increased risk from stress. Psychol. Med. 53:1991;322-331.
34. Perennec J., Pocholle W.P., Hatt P.Y., Crozatier B. Cardiac ultrastructure abnormalities in Syrian hamsters with spontaneous cardiomyopathy or subjected to cardiac overloads. Basic Res. Cardiol. 87:1992;54-64.
35. 2+ channel coupled to glutamate exocytosis. Eur. J. Pharmacol. 226:1992;343-350.
36. 1 myosin isozyme decrement in the adult rat heart. J. Mol. Cell. Cardiol. 26:1994;293-296.
37. Reiter R.J., White T., Lerchl A., Stokkan K.A., Rodriguez C. Attenuated nocturnal rise in pineal and serum melatonin in a genetically cardiomyopathic Syrian hamster with a deficient calcium pump. J. Pineal Res. 11(3-4):1991;156-162.
38. 2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc. Drugs Ther. 1:1988;677-686.
39. 2+ kinetics in the cardiomyopathic hamster heart. Am. J. Physiol. 259:1990;H1533-H1543.
40. Sonnenblick E.H., Fein F., Capasso J.M., Factor S.M. Microvascular spasm as a cause of cardiomyopathy and the calcium-blocking agent verapamil as potential primary therapy. Am. J. Cardiol. 55:1985;179B-184B.
41. Sorenson A.L., Tepper D., Sonnenblick E.H., Robinson T.F., Capasso J.M. Size and shape of enzymatically isolated ventricular myocytes from rats and cardiomyopathic hamsters. Cardiovasc. Res. 19:1985;793-799.
42. Tian R., Nascimben L., Kaddurah-Daouk R., Ingwall J.S. Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J. Mol. Cell. Cardiol. 28:1996;755-765.
43. Van Zwieten, P.A., 1985. Drug Targets in Unstable Angina: Current Concepts and Management. Schattauer Verlag, pp. 151-157.
44. Venkatakrishnan R., Rourke A.W. The structure, function and turnover of cardiac myosin in normal and myopathic Syrian hamsters. Lab. Invest. 41:1979;198-205.
45. Verdonck L., Borgers M., Verdonck F. Inhibition of sodium and calcium overload pathology in the myocardium: a new cytoprotective principle. Cardiovasc. Res. 27:1993;349-357.
46. Voisin E.M., Ruthsatz M., Collins J.M., Hoyle P.C. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regul. Toxicol. Pharmacol. 12:1990;107-116.
47. Wrogemann K., Nylen E.G. Mitochondrial calcium overloading in cardiomyopathic hamsters. J. Mol. Cell. Cardiol. 10:1978;185-195.